glp-1 drug news Study finds receptor agonists target fat over muscle for weight loss Fmr. FDA Commissioner weighs in

The FDA has issued multiple warnings about compounded GLP-1 products, citing concerns that include dosing errors, adverse events, unapproved ingredient forms, and variability in product quality

DSIP was not identified by name in the reviewed 2026 WADA list

Disruptions in the gut microbiome can adversely affect the absorption and metabolism of critical micronutrients, including iodine and selenium, thereby influencing thyroid hormone synthesis and immune regulation

Nature 617 , 581591 (2023)

We reviewed Sikiric 1993-2026 (Zagreb, over 150 BPC-157 papers), the AJSM 2026 systematic review (35 preclinical studies), the 2026 pilot PK study in two healthy subjects, and the February 2026 STAT review

Drugging IGF-1R in cancer: New insights and emerging opportunities